Journal
GENETICS IN MEDICINE
Volume 5, Issue 5, Pages 385-392Publisher
NATURE PUBLISHING GROUP
DOI: 10.1097/01.GIM.0000087990.30961.72
Keywords
pharmacogenomics; race; genetic discrimination
Categories
Funding
- NHGRI NIH HHS [5 R01 HG02191-02] Funding Source: Medline
Ask authors/readers for more resources
Objectives: To ascertain attitudes of prospective patients relevant to the delivery of race-based pharmacogenomics. Methods: Written anonymous survey and qualitative responses in two sets of reactance format focus groups over-sampled for minority groups in urban, suburban, and rural communities conducted from February through April, 2002 [N = 104] and August through November, 2002 [N = 120]. Results: Participants do not associate races exclusively with continental clusters. They have incomplete knowledge of their recent ancestors (39.6% do not know all their biological grandparents). They would be highly suspicious of race-labeled drugs; with 47.5% saying they would be very suspicious of their safety and 40.6% indicating they would be very suspicious of their efficacy. A substantial minority of African-American participants (13.2%) would prefer to take the drugs designated for European Americans. Effect of discussion of race-based medicine on racial attitudes is ambiguous. Conclusions: Patient knowledge of ancestry and suspicion of race-designated drugs constitute substantial barriers that need to be incorporated in judging the likely effectiveness of race-based pharmacogenomics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available